Zydus Cadila gets USFDA nod for drug to treat high blood pressure in lungs

PTI New Delhi | Updated on March 29, 2019 Published on March 29, 2019

File photo

Drug maker Zydus Cadila on Friday said it has received the final approval from the US health regulator to market Ambrisentan tablets, used to treat high blood pressure in the lungs, in the American market.

The Ahmedabad-based group has received the approval from the US Food and Drug Administration (USFDA) to market the drug in strengths of 5 mg and 10 mg, Zydus Cadila said in a statement.

The product would be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. The sales of Ambrisentan tablets USP in the US market stood at $943 million (about Rs 6,500 crore) last year.

Zydus said it now has 258 approvals from the USFDA and has so far filed over 350 abbreviated new drug applications (ANDAs) since the commencement of its filing process in 2003-04.

Shares of Cadila Healthcare, the listed entity of the group, were up 3.16 per cent up at Rs 346.35 on the BSE today.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on March 29, 2019
This article is closed for comments.
Please Email the Editor